📈 Stocks 🌍 GLOBAL

BioMarin and Ascendis Resolve Patent Dispute, Shares Rally 5% on Settlement

BioMarin and Ascendis settle a global patent dispute over the drug Yuviwel, with BioMarin securing a 20% US royalty stream and Ascendis gaining unrestricted commercial freedom.

📅 September 12, 2026 🕐 1 min read

2 assets impacted. Net bias: 2 Bullish, 0 Bearish, 0 Neutral. Strongest signal: BMRN ↑ 7/10 (68% confidence).

📊 Affected Assets (2)

BMRN

Bullish 🤖 68%

📅 Short-term 🌍 US · Explicit

BioMarin gains a royalty stream from Ascendis's Yuviwel sales, removing litigation uncertainty.

ASND

Bullish 🤖 65%

📅 Short-term 🌍 US · Explicit

Ascendis resolves patent litigation, securing commercial freedom for Yuviwel despite royalty payments.

🎯 Key Takeaways

BioMarin secures a 20% royalty on US net sales and 18% internationally for Yuviwel through May 2030.
The settlement terminates all pending litigation, including the US International Trade Commission investigation.
Ascendis gains full commercial flexibility to scale Yuviwel, though the royalty burden will impact long-term net margins.

📝 Executive Summary

BioMarin Pharmaceutical and Ascendis Pharma have reached a binding settlement to end global patent litigation regarding the achondroplasia drug Yuviwel. The agreement grants Ascendis a worldwide license while securing a lucrative, multi-year royalty stream for BioMarin through 2030, effectively removing significant legal uncertainty for both firms.

❓ FAQ

What does the settlement mean for BioMarin?

BioMarin gains a consistent, long-term royalty stream from Yuviwel sales without incurring the commercial risks or costs associated with marketing the drug.

How does this impact Ascendis Pharma?

Ascendis removes a major legal overhang that threatened the availability of its drug, allowing for unrestricted global commercialization at the cost of a multi-year royalty obligation.

📰 Related Articles

🏷️ Tags

📰 Source

🔗 View Original Article